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Functional and Biochemical Alterations of Platelets in
Atherosclerosis and Thromboembolism
Orhan N. Ulutin, MD*

In atherosclerosis, platelets appear to circulate in an activated state. Our findings are based on results obtained
from 240 patients. These platelets demonstrated an increased degree of surface activation and an increased
amount of aggregation. Platelet aggregation was also demonstrated by a heightened sensitivity to adrenalin and
ADP. Greater than normal secretion of ADP, PF-4, platelet
fibrinogen, and platelet antiplasmin was noted. Platelet
antiplasmin was increased, whereas platelet antithrombin
III was decreased. Membrane transport of glucose was
found to be defective in atherosclerosis. There appears to
be no alteration in the phospholipid distribution, although

the amount of phospholipids increases. The order of secretion of phospholipids in ADP and
collagen-induced
secretion was found to differ in platelets from atherosclerotic patients when compared to normal platelet
populations. The availablillty
of phospholipids rich In
arachidonic acid was enhanced. Also, in atherosclerosis,
we found a decrease in platelet c-AMP and an increase In
c-GMP. The balance between TXA2 formation in platelets
and PC/2 formation by the vessel wall is important in
determining whether thrombus formation is encouraged or
prevented.

M any investigators have suggested that the "prethrombotic state" or the "hypercoagulable stage" occurs in
patients with atherosclerosis as well as those with thromboembolism (1-4). Experiments have shown that certain
coagulation factors are increased and circulate in their
activated form in such patients. A condition characterized
by heparin resistance, the rapid elimination of heparin
with resultant low blood heparin levels (5-7), and subsequent decreased plasma antithrombin III levels has been
reported. This situation encourages thrombus formation.
Other changes associated with atherosclerosis which
could promote thrombus formation include: 1) alteration
ofthe vessel wall and lipids; 2) a decreased platelet halflife indicating increased platelet utilization (8,9); 3) decreased fibrinolytic activity; and 4) decreased plasma
fibrinogen levels.

Our findings are based on results obtained from 240 patients seen over the last decade (5). Lipids were typed on
115 patients, and 92 were found to have type II hyperlipoproteinemia. The hyperfunction of platelets that we
observed parallels lipid alterations (14) and agrees with
data previously reported by Colman (15).

Surface Response
Platelet adhesion is increased in patients w i t h atherosclerosis. Preliminary findings in this area were first
reported in patients with ischemic heart disease (16) and
were confirmed later (10,17-19). We observed that same
phenomenon in our laboratory using the methods of Salzman and Hellem.
Such platelet hyperadhesion parallels elevations in
fibrinogen and von Willebrand factor (Table I) observed in
these same patients (2,10,20-21). In atherosclerosis, the
elevation of fibrinogen and von Willebrand factor levels
stimulates platelet adhesion and interaction with the subendothelium. This correlation has been confirmed by Fuster and Bowie in experiments w i t h pigs having the
homozygote form of von W i l l e b r a n d ' s disease. They
found that atherosclerosis was not produced (22) because
the impaired platelet subendothelial interaction present
prevented the formation of atheromatous plaques.

Since several extensive reviews of platelet function have
already been published (10-13), we will not delineate the
full scope of platelet physiology and biochemistry. Instead, we will describe the platelet changes and bioc h e m i c a l a l t e r a t i o n s in a t h e r o s c l e r o s i s
and
thromboembolism observed in our laboratory.
* Division of Haematology and Hemostasis Research Unit, Cerrahpasa
Medical Faculty, Istanbul University, Istanbul, Turkey
Address reprint requests to Dr. Ulutin, Division of Haematology and
Hemostasis Research Unit, Intemal Clinic, Cerrahpasa Medical Faculty
Istanbul University, Istanbul, Turkey

Rebuck and co-workers (23-24) devised a method that
utilized transmission electron microscopy to measure the
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TABLE I
Coagulation Studies and Platelet Parameters from Patients With Atherosclerosis and Normal Subjects <^''">
Test Procedures
Fibrinogen (mg7o)
(N:25)

Control

Atherosclerosis

248.48 ± 38.24

375.68 ± 73.26

P Value

p<0.001

FVIII vWF (u%)
(N:18)

135.4 ± 15.8

87.33 ± 12.3

p<0.001
76.5 ±11.6

Hellem II glass retension (%)
(N:15)

42.8 ± 8.6

ADP max. amp. mm 0.1 /ml
(N:25)

26.48 ± 8.636

Adrenalin max. amp. mm 0.25 ml
(N:25)

42.69 ± 16.834

p <0.001
55.88 ± 28.16
p<0.001
73.4 ±29.96
p<0.001

TABLE II
Averaged Platelet Differential Count Using Electron Microscopy in Control Subjects and Patients with Atherosclerosis*
Platelet Types (%)

Round (%)
Dentritic (%)
Intermediate (%)
Spread (%)
Aggregates per 100
single platelets

Control

Atherosclerosis

Aspirin

(N:16)

(N:4)

Dipyridamole
(N:4)

Indobufen

(N:10)
4.5±2.6
53.6±8
21.4±4.2
ia,5±5,6

2.6±2.4
20.8±6.2
27.7±6,4
48,9±11,6

32.4
38.4
11.5
17.7

17.7
47.6
14.9
19.8

27.6
41.4
13.8
17.2

6.4±4,2

36.0±14.6

9.4

14.2

10.8

(N:6)

* Selected antiplatelet agents were evaluated in the abnormal platelet group.
when platelet aggregometry is used. In patients with diabetes and atherosclerosis, lower than normal concentrations of aggregating agents are required to induce both
aggregation and secreation (10,17,20,29-30). Under in
vivo conditions, this excess sensitivity undoubtedly facilitates platelet aggregate formation and may potentiate the
formation of thrombi and the occurrence of transient ischemic attacks.

degree of surface activation and amount of aggregation
exhibited by platelets when they were exposed to a standardized surface (Formvar film) under controlled conditions. U l u t i n , et al (25-27) and W a l s h , et al (28)
independently used this procedure to monitor platelet
populations from patients with transient ischemia, cardiovascular disease, and atherosclerosis. Platelet differential counts from patients with atherosclerosis differed from
those of normal subjects (Table II). Both the percentage of
activated platelets (spread forms) and the number of aggregates were elevated. Increases in platelet adhesiveness
and the number of activated forms were more pronounced
in the prethrombotic stage and during documented transient ischemic attacks. Antiplatelet drugs, such as aspirin,
dipyridamole and Indobufen, normalized the abnormal
surface activation, as reflected by a decrease in the percentage of spread forms and a concomitant increase in the
number of round forms.

Secretion
An initial injury that disrupts the endothelial layer of the
vessel wall will cause platelets to stick and release a variety
of factors. We found that PF-3 (lipoprotein platelet thromboplastin, a procoagulant activity) was increased in patients with atherosclerosis (21), while the osmotic fragility
ofthese platelets remained normal (31). PF-3 activity isalso
reportedly increased in patients with transient cerebral
ischemia and hyperbetalipoproteinemia (32).

Increased platelet aggregability is also seen in patients
with atherosclerosis and thromboembolic phenomenon
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TABLE III
Secretion of Platelet Fibrinogen, ADP and PF-4 from Platelets Stimulated with Adrenaline, ADP, and Collagen
Unstimulated

Adrenaline

ADP

Collagen

Control (N:23)
% Secretion

119.08 ± 5.22

71.3 ± 10.9
40.2

61.4 ± 7.4
48.5

54.5 ± 5.9
54.3

Atherosclerotics (N;12)
% Secretion

123.36 ±

61.2 ± 9.7
50.4

58.4 ± 10.7
42.7

48.8 ± 10.6
60.5

Platelet Fibrinogen
(ug/tO^ platelets)

Platelets

Supernatant

Control (N:26)
% Secretion

0.720 ± 0.39

1.470 ± 0.36
67

Atherosclerotics (N:26)
% Secretion

0.326 ± 0.38

1.509 ± 0.39
82

ADP
(mg 3x10' platelets)

Control {N:26)

62.04 ± 1.52

Atherosclerotics (N:26)

p <0.001
49.90 ± 2.56

PF-4 (Sec.)

In 1968, we reported that PF-4 was a releasable factor (33),
and in the same year, Farbiszewski, et al (34) confirmed this
finding. They reported that PF-4 was secreted from platelets
during intravascular coagulation and thrombosis. Akman
showed (35,36) that the same inducer released more PF-4
from platelets of patients with atherosclerosis than from
controls. Later, the same enhanced release phenomenon
was observed (2,10,19,20,29,37) for the secretion of ADP
and platelet fibrinogen (Table III).

Measurement of another releasable factor, platelet antithrombin 111, revealed a contrasting decrease (46,47),
which potentially would expose circulating platelets to the
action of available thrombin (Table V). We observed this
deficiency in all our patients with ischemic heart disease
and myocardial infarction. Recently, a new clinical entity
was described (48) in which family members exhibited
multiple thrombosis related to hypercoagulability caused
by a platelet antithrombin 111 deficiency.
In our series, a decrease in the levels of both plasma
antithrombin III and platelet antithrombin 111 has been
observed among patients with atherosclerosis, ischemic
heart disease, myocardial infarction, and transient ischemic attacks. Moreover, in these cases, heparin disappears
rapidly, and the duration of greater antithrombin III activity
decreases after heparin injections (21). We believe that the
deficiency of plasma antithrombin III in patients with
atherosclerosis is related to the heparin deficiency and to
the rapid elimination of heparin. It should also be noted
that there are rare families with a congenital absence of
antithrombin III (49-51).

Similar changes have been noted in the preceding stage of
chronic diffuse intravascular coagulation (DIC). In DIC, a
release reaction by the circulating platelets creates an
acquired storage pool deficiency, which can be demonstrated by biochemical and ultrastructural studies (10,
38-40). Secreted PF-4 is demonstrated extracellularly, and
the Mayo Clinic investigators interpret its rise as indirect
evidence of sequestration and consumption of platelets in
the blood clotting process (41,42). In atherosclerosis and
thromboembolism, the presence of PF-4 and betathromboglobulin (p-TG) have diagnostic value (35,36,43,44).
Since we have observed great similarity between atherosclerosis and the preceding as well as the early compensated stages of chronic DIC, it is possible that continuous
intravascular coagulation occurs in some cases of atherosclerosis (Table IV).

Another releasable platelet substance promotes the proliferation of smooth muscle cells. This close relationship
between platelets and the early sign of atherosclerosis
(i.e., smooth muscle cell proliferation) is important because
in multiple vessel injury platelets seem to play a role not
only in thrombus formation but also in the intimal thickening and ultimately the pathogenesis of atherosclerosis
(52,53).

We also demonstrated a significant increase in platelet
antiplasmin (a releasable factor) in patients with atherosclerosis (37,45) when compared to normals (Table V).
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TABLE IV
Stages of Disseminated Intravascular Coagulation and Averaged Laboratory Findings in Ten Cases
Compensated
Stage

Preceding
Stage

Decompensated
Stage

Fibrinogen

Increased

Normal

Decreased

Prothrombin

Normal

Slightly decreased

Decreased

Factor V l l l / v W F

Increased

Increased or n o r m a l

Decreased

Platelet c o u n t

Normal or
elevated

Normal or slightly
decreased

Decreased

PF-4

Normal

Decreased

Decreased

ADP-release

Increased

PF-4 - release

Increased

ADP c o n t e n t of platelets

Normal

Decreased

Decreased

T h r o m b i n time

Shortened

Normal c r p r o l o n g e d

Prolonged

ELT

Prolonged

Normal or shortened

Shortened

PDP

Normal

Increased

Increased

—
—

—
—

F i b r i n o g e n (mg %)

540 ± 8 0

310±95

92 ± 4 5

Prothrombin
( u / m l ) (two-stage)

240 ± 3 0

160±40

95±38

0,04-0,06

0,2-0,02

0.0

82 ± 16
1,950±0,350

15±7
0.310±0.110

0.240±0.07

6 + 3

22 ± 8

52 ± 24

Total PF-4
( U / h r / 1 0 ' platelets)
ADP release %
ADP ( m g / 3 x 1 0 i ° platelets)
FDP mg %

TABLE V

phospholipid prostacyclin synthetase enzyme. Furthermore, it is now known that prostacyclin is the strongest
inhibitor of platelet aggregation and secretion and that the
balance between TXA2 and prostacyclin partially dictates
either the formation or prevention of thrombosis (20,29,
54,55) (Figs. 1,2). It is thus significant that experimental
evidence indicates increased thrombus formation atthe site
of injured or disrupted endothelium where PCb formation
is either decreased or absent (55). In addition, it has been
shown in humans that PCb-like activity is absent in atheromatous plaques.

Comparison of Platelet Antiplasmin and
Platelet Antithrombin III Levels in Patients with
Atherosclerosis and Normal Subjects

Platelet a n t i p l a s m i n
u/cumm
Inhibition (%)

Control

Atherosclerosis

2.4 ± 0.8

10 + 1.9
12

3.5
p <0.001

Platelet a n t i t h r o m b i n III
Immunologic method
/Ltg/tO^ pit.

14.74 ± 1.9

8.84 ± 1.59

Rivanol m e t h o d
Unit/Thrombin

1.20 ± 0.04

1.04 ± 0.06

1.6 ± 6.08

0.9 ± 0.2

Chromogenic Substrade
2239 % A t h , III,

—

In experiments with rabbits fed on atherogenic diets, a
decrease in spontaneous and arachidonic acid-induced
prostacycline formation was noted in the mesenteric artery
and aorta. At this stage, the platelets are presumably normal. Only hyperaggregability to ADP can be shown, due to
a decreased level of c-AMP, which in turn relates to a
probable deficiency of PGb. After some time, however,
arachidonic acid metabolism accelerates. As a result, platelet TXA2 generation increases and PGI2 formation decreases, both of which increase the risk for thrombus
formation (56). Using isolated platelets from atherosclerotic
patients, Yardimici and Emekli from our laboratory have
shown that the increase in c-AMP and the decrease in c-

Another factor released by platelets also causes vasoconstriction of the vessel wall. However, because the prostacyclin (PCI2) formed n the vessel is a vasodilator, it
diminishes the action of this material.
More specifically, studies of prostacyclin (PCI2) have
shown that it is formed in the endothelial cells of the vessel
wall in the arachidonic acid-endoperoxide pathway by a
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Platelets

Endothelial
Platelet

cells

stimulation
VWF

Arachidonic

acid

PGG„ PSH
2• ! 2
P r o s t a c y c l i n . Synthetase

Fibrinolytic

System Activators

Fig. 1
Prostaglandin pathways in the vessel wall and platelets. The balance between TXAj and PGI2.

CMP were significant when compared to normal platelets
(57). These findings lend further support to the concept that
activated platelets circulate in atherosclerotic patients.

lated from normal subjects and patients w i t h atherosclerosis. When either ADP or collagen (20,29,58-61)
was the inducer, no differences between the order of
phospholipid distribution occurred. The order was as follows: phosphotidyl c h o l i n e (PC) > phosphotidyl e t h anolamine (PE) > spinogomyelin (SPH) > phosphotidyl
serine (PS) > , and phosphotidyl inositol (PI). However, in
atherosclerotic patients, the quantities of phospholipids
were increased.

These observations reveal the importance of TXA2 as an
inducer of platelet aggregation produced by the platelets,
the formation of PGb (an inhibitor of platelet aggregation
produced by the vessel wall), and the balance between
these two materials. We believe that thrombus formation is
facilitated by decreased PGb synthesis from arachidonic
acid in the endothelial cells or by an increased formation of
TXA2 again from arachidonic acid, but in the platelets. Ifwe
decrease TXA2 formation in platelets or inhibit its release,
thrombus formation is hampered.

Depending on the inducer, the secretion of phospholipids
(and therefore their availability) differed when normal
platelets were compared with atherosclerotic platelets. This
dependency was observed in both groups (58,61). In normal subjects, the sequence of secretion after induction with
ADP was SPH > Pl > PC > PS > PE (Fig. 3); whereas with
collagen, it was PI > PS > SPH > PC > PE (Fig. 4). Using
atherosclerotic platelets, the sequence of secretion with
ADP was altered to PI > SPH > PS > PC > PE; and with
collagen itwas also changed: PS > PC > PE > PI > SPH. In

Phospholipid Distribution and Quantitation
We also investigated both the distribution order of phospholipids in the platelet membrane and their sequence of
secretion during the release phenomenon for platelets iso-
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Platelet
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Mg++
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• Activator

Fig. 2

atherosclerotic patients, PS and PI (Fig. 5) showed an
increased amount of release (P > 0.001), whereas the
release of SPH and PC decreased significantly and PE
remained changed. In collagen-induced release, a greater
release of PS, PE and PC (Fig. 6) was observed in atherosclerotic patients. On the other hand, there was a significant decrease in Pl and SPH release.

in thromboxane synthetase activity in patients with atherosclerosis as well as those with diabetes mellitus (30,62).
Recently, Gursoy (Aktulga) demonstrated that when the
platelets of atherosclerotic patients were induced with
collagen (63), their PGF2Q; formation was significantly
higher than that of normal subjects (63).

In atherosclerosis, the phospholipids secreted early in the
sequence are those rich in arachidonic acid. These observations gained importance when it was found that membrane phospholipids, arachidonic acid, PGE2, PGF2a and
TXA2, play key roles in platelet aggregation, secretion, and
thrombus formation (20,29). Among the other findings that
support this view are the increase in platelets of phospholipids rich in arachidonic acid (20,29) and the increase

Membrane Transport
Yardimci from our group (34) has shown a defect in the
membrane transport of glucose in atherosclerosis. In patients with atherosclerosis, diabetic or nondiabetic, there
was a significant decrease in platelet glucose transport
when compared to normal subjects (Figs. 5-8). Thus, we
can conclude that these patients have a defect in carbohydrate metabolism at the cellular level.
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total
release -

N

P

N

P

N

P

N

P

Fig. 3

Fig. 4

ADP-induced platelet phospholipid release in normal subjects (N) and in
atherosclerotic patients (P).

Collagen-induced platelet phospholipid release in normal subjects (N) and
in atherosclerotic patients (P).

\

>—

4t

*f

Atherosclerosis

10

20

Time

30

(mm)

[ g l u c o s e ] X10

Fig. 5

M

Fig. 6
Kinetics of glucose transport by human platelets isolated from normal
subjects and f r o m atherosclerotic patients. The assay is performed at
37°C. Normal subjects, N:6; atherosclerotic patients, N:7 (54).

Time course accumulation of glucose by human platelets isolated from
normal subjects and from atherosclerotic patients. The final '*C-glucose
concentration In the incubation medium was 1X10-5M and the assay
temperature was 37°C. Each point represents mean ± SE. Normal
subjects, N : 2 1 ; atherosclerotic patients, N:26 (54).
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Fig. 8

Double reciprocal plot of concentration dependence curve of glucose
transport by human platelets isolated f r o m normal subjects. Each point is
mean ± SE for N:6 (54).

The effect of metabolic inhibitors and non-metabolizable glucose analogues on gluscose transport by control human platelets and those from
atherosclerotic patients. Final glucose concentration was 1x10 ^IVI. Assay
temperature was 37°C; the amount of glucose accumulation is measured
at 10 min of incubation times. Bars represent mean ± SE, N:7 for normals
and N:14 for atherosclerotics. The accumulation at 4°, w i t h KCN, w i t h
DNP, w i t h D O G , and w i t h 30MC compared to theamount accumulated at
37° is all highly statistically significant; w i t h oubain it is significant for
normals. For atherosclerotics the differences are not significant (54).

Summary
In atherosclerosis, platelets undergo functional changes
including increases in adhesion, surface activation, and
aggregation. These changes would appear to facilitate
thrombus formation. The balance between TXA2 formation
in platelets and the PGI2 formation by the vessel wall is also
important in thrombus formation. We believe thatthe most
important observation in atherosclerosis about platelets is
that they circulate in an activated state.
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